Aims Incretin-based antihyperglycemic therapies increase intestinal mucosal expansion and polyp growth in mouse models. We aimed to evaluate the effect of dipeptidyl peptidase-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonists (GLP-1ra) initiation on colorectal cancer incidence. Methods We conducted a cohort study on US Medicare beneficiaries over age 66 from 2007 to 2013 without prevalent cancer. We identified three active-comparator and new-user cohorts: DPP-4i versus thiazolidinediones (TZD), DPP-4i versus sulphonylureas (SU), and GLP-1ra versus long acting insulin (LAI). Follow-up started from 6 months post-second prescription and ended 6 months after stopping (primary astreated analysis). We estimated hazard ratios (HR) and 95 % confidence intervals (CI) for incident colorectal cancer adjusting for measured confounders using propensity score weighting.
Introduction
Incretin-based therapies, glucagon-like peptide-1 receptor agonists (GLP-1ra) and dipeptidyl peptidase-4 inhibitors (DPP4i), are commonly used second line therapies in the management of type 2 diabetes mellitus (DM) [1] . GLP-1ra are injected peptides, analogs, or natural mimetics of human GLP-1, which enhance glycemic control by promoting glucose-dependent insulin secretion, suppressing fasting glucagon secretion, regulating gastric emptying and reducing appetite [2] . DPP-4 is the enzyme which degrades GLP-1 and as well as other biologically active peptides. Thus, DPP-4i exert their antihyperglycemic action by inhibiting this enzyme increasing endogenous incretin hormones levels [3] .
GLP-1ra were first introduced in the United States in 2005. Exenatide was the first in class followed by liraglutide in 2010 and albiglutide and dulaglutide in 2015 [4] . They have been recommended because of their powerful efficacy, lack of intrinsic hypoglycemia as an adverse effect, and associated weight loss; however, market penetration has been limited related to nausea, the need for injection, high cost, and concerns about safety, particularly with regard to cancer and pancreatitis [1] . DPP-4i were approved in 2006. Sitagliptin was the first in class, followed by saxagliptin (2008), linagliptin (2011) and alogliptin (2012) [5] . The DPP-4i have been recommended related to reasonable efficacy, but excellent tolerability without nausea, weight-gain, or hypoglycemia. Furthermore, large-scale cardiovascular outcome trials have been completed demonstrating no substantial safety concerns, particularly with market-leading sitagliptin [6] [7] [8] .
GLP-1 receptor signaling has been found in genetically predisposed mice to stimulate intestinal mucosal expansion, increased polyp number, and growth. In mouse studies, exenatide was observed to increase small intestinal growth over 14-16 weeks after treatment and stimulated growth factor expression in colon polyps [9] . Currently, there are no population-based studies, which report the effect of incretinbased agents on the colorectal cancer incidence.
Methods
We registered the study protocol in the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) electronic register of studies. (http://www.encepp. eu/encepp/viewResource.htm?id=3411). Our study was approved by the University of North Carolina at Chapel Hill Institutional Review Board.
Study design
We conducted an active comparator, new user cohort study in a 20 % random sample of U.S. Medicare beneficiaries over age 66 from 2007 to 2013 [10, 11] . We identified three pairs of second line antihyperglycemic treatment initiators, who are likely to have similar stages of diabetes mellitus progression: DPP-4i versus thiazolidinediones (TZD), DPP-4i versus sulphonylureas (SU), and GLP-1ra versus long acting insulin (LAI) [12] . These antihyperglycemic initiators were identified after requiring a 12-month Bdrug-free^period (6 months for GLP-1ra versus LAI cohorts due to sample size) during which they could be treated with antihyperglycemic drugs other than the ones being compared (except for short-acting insulin for GLP-1ra versus LAI). All participants were required to have continuous enrollment in Medicare parts A, B, and D for 12 months (6 months part D for GLP-1ra versus LAI) before the first prescription.
To increase the probability that patients actually took the dispensed medications, study participants were required to refill their prescription within the 30-day grace period (90 for injections) of the days' supply of the first prescription. The date of the second prescription was defined as the baseline. Patients with any prevalent cancer related diagnosis or procedure codes (except for non-melanoma skin cancer: see Online Resource Appendix Table S1 ) during the 12-month period prior to the first prescription and between the first and the second prescriptions were excluded [13] .
Outcome
The primary outcome of interest was colorectal cancer defined as at least 2 ICD-9-CM diagnosis codes of 153.X or 154.0 or 154.1 within 2 months. We required a second diagnosis code within 2 months after the first code to minimize the problem of rule-out diagnosis codes submitted as a part of surveillance and to maximize specificity [14] . We also included carcinomain situ (230.3 and 230.4) and colorectal polyps or adenomas (45.42 and 48.36) in our outcome definition as secondary analyses.
Follow-up and analyses
For our primary analysis, we assumed a 6-month lag period following second prescription to allow for an induction and latent period (delayed effect of the drug on cancer and preclinical phase) and excluded patients with incident colorectal cancer during this period [15] . We followed the remaining patients until switching, stopping, or augmenting the drug (plus 6-month lag time to allow for a latent period), the incidence of the outcome, any cancer (except non-melanoma skin cancer), all-cause mortality, end of enrollment in Medicare Parts A and B, or December 31, 2013, whichever came first. We also performed an analysis in which patients were not censored when they stopped/switched/augmented therapy (first treatment carried forward).
Confounding control
Our first line of confounding control was by design comparing pairs of initiators of treatments recommended for similar stages of progression of type 2 diabetes [12, 16] . Potential remaining confounders (Tables 1 and 2) were assessed before the first drug prescription date. We estimated separate propensity scores (PS) for each treatment pair predicting the probability of initiating incretins versus the comparator based on potential confounders using multivariable logistic regression [17, 18] . To implement confounding control, we then assigned a weight of 1 to patients in the incretin cohorts and a weight of the propensity odds (PS/(1-PS)) to active comparators (TZD, SU, or LAI) [19] . This weighting allows us to estimate the unconfounded treatment effect in a population defined by the covariate distribution of patients initiating incretin drugs (assuming no unmeasured confounding). We then fitted PS weighted Cox proportional hazards models with a robust variance estimator and weighted Kaplan-Meier survival curves to estimate the effect of initiation of incretins on the time to colorectal cancer. We ran separate Cox models stratified by the duration of treatment to assess the estimates over time.
Assessment of potential bias
It is possible that patients initiating incretins are more likely to undergo diagnostic or screening procedures leading to earlier diagnosis of preclinical cancer, which could bias our results [20] [21] [22] . We checked for this potential differential detection by comparing the probability of having a colonoscopy in a year prior to and 6 months after the baseline prescription between our cohort pairs. We also excluded varying small proportions of patients in both tails of the PS including patients treated contrary to prediction (i.e., patients initiated on incretin drugs with the lowest PSs and patients treated with the comparator with the highest PSs) since it is plausible that some unmeasured characteristic made their physicians Boverridet he predicted treatment decision, which can lead to unmeasured confounding [23] . We varied the lag period prior to the start of follow-up from 6 (primary analysis) to 0, 12 and 24 months to check the robustness of our assumptions. Other sensitivity analyses varying the censoring patterns are presented in Online Resource Appendix Tables S10 and S11.
Results
We present baseline characteristics of the patients initiating DPP-4i, TZDs, and SUs in Table 1 . Compared with TZD initiators, DPP-4i initiators were slightly older, less likely to be men, and more likely to be white. DPP-4i initiators were more likely to have major comorbidities and use statins, diuretics, angiotensin receptor blockers, and beta blockers than TZD initiators. Among the DPP-4i (different from the above DPP-4i initiators) and SU initiators, DPP-4i initiators were less likely to be men and had a higher prevalence of diabetic neuropathy, retinopathy, nephropathy, hypertension, and connective tissue disorders than SU initiators. We present baseline characteristics of the patients initiating GLP-1ra and LAI in Table 2 . GLP-1ra initiators were younger and generally healthier than LAI initiators with fewer major comorbidities. Both incretins (DPP-4i in both cohort pairs and GLP-1ra) were more likely to be on metformin, use preventive services such as lipid testing and flu vaccination, less likely to have hospital admissions, and more likely to have outpatient visits. The magnitude and direction of the association of each covariate with the treatment choice between GLP-1ra and LAI as estimated in the PS model is presented in PS model parameters column in Table 2 . Covariate differences between our cohort pairs were removed after the propensity score weighting. One thing of note is that both incretins were more likely to be prescribed after 2010 than comparators, and this trend was most pronounced for DPP-4i versus TZD. In the DPP-4i versus TZD cohort pair, patients were allowed to be on antihyperglycemic drugs other than DPP-4i and TZD during the washout period. Similarly, in the DPP-4i versus SU cohort pair, patients could be on antihyperglycemic drugs other than DPP-4i and SU during the washout c Pseudo-population of TZD initiators weighted to the distribution of covariates of the DPP-4i initiators using the propensity score to balance covariates (and therefore control for confounding) d Pseudo-population of SU initiators weighted to the distribution of covariates of the DPP-4i initiators using the propensity score to balance covariates (and therefore control for confounding) e Measured in the 12 months before drug initiation (the date of the first prescription)
f Measured in the 6 months before drug initiation (the date of the first prescription) In Table 3 , we present the number of events, the duration of treatment, the crude and adjusted (weighted) hazard ratios with their 95 % confidence intervals for the various cohorts and comparisons. For the primary as treated analyses, there were 104 colorectal cancer events among 39,334 DPP-4i initiators and 63 among 25,786 TZD initiators, and the fully adjusted HR was 1.17 (95 % CI: 0.88, 1.71). For the DPP4i and SU comparison, there were 73 colorectal cancer events among 27,047 DPP-4i initiators and 266 events among 76,012 SU initiators. The fully adjusted HR was 0.98 (95 % CI 0.74, 1.30). The number of colorectal cancer events in 5600 GLP1ra initiators was less than 11, which is the minimum cell size that our data use agreement with the Centers for Medicare and Medicaid Services (CMS) allows us to publish. The fully adjusted HR for GLP-1ra initiators versus LAI initiators was 0.82 (95 % CI 0.42, 1.58). We present weighted KaplanMeier plots for all treatment comparisons in Fig. 1 . The median duration of treatment ranges from 0.7-1.2 years for as treated analyses and 2.0-3.3 years for first treatment carried forward analyses (where treatment changes were uncensored), both of which revealed similar results (Table 3) .
Our secondary analyses examined the composite outcome of invasive and in situ colorectal cancer and cancer precursors (polyps/adenomas) (Online Resource Appendix Table S4 ). The fully adjusted HR was 0.95 (95 % CI 0.74, 1.23) for DPP-4i versus TZD and 1.08 (95 % CI 0.90, 1.31) for DPP4i versus SU. The fully adjusted HR for GLP-1ra versus LAI was 0.76 (95 % CI 0.48, 1.23).
Changing our assumption about induction and latent periods (to allow for a delayed effect of antihyperglycemic drugs on colorectal cancer and a preclinical phase) to 0, 12, and 24 months and stratifying the duration of treatment to assess the effects over time reveal consistent hazard ratios similar to our primary results (Online Resource Appendix Tables S5, S6 , and Appendix Figures S1-S3) . Assessment of potential detection bias also reveals similar proportions of colonoscopy between our cohorts. Other sensitivity analyses also suggested the robustness of our primary analyses (Online Resource Appendix Tables S7-S12).
Discussion
In this first population-based cohort study addressing the realworld effects of incretins on colorectal cancer risk, we observed no short-term effect of DPP-4i and GLP-1a initiation on the risk for colorectal cancer compared with initiation of alternative treatments indicated for similar stages of diabetes duration and severity. Like previous studies on antihyperglycemic treatments and cancer risk, our study was restricted to short-term use of incretins due to the real-world dynamics of antihyperglycemic treatments where only a small proportion of patients stay on the same drug class for prolonged periods of time [22] . This dynamic in treatments makes it very difficult to study long-term effects of treatments on cancer risk but also limits any potential public health impact on cancer risk.
To allow for some delay in the effect of the drug on late stage carcinogenesis [15] , we allowed a 6-month lag period before follow-up and after censoring for treatment changes. Varying this lag period did not substantially change our PS propensity scores, OR odds ratio, CI confidence intervals, SMR standardized morbidity ratio (weight of 1 given to GLP-1ra users and PS/(1-PS) to LAI users, where PS stands for propensity score), s.d. standard deviation a Initiation or new use defined as dispensing at least 2 prescriptions within 90 days after the days' supply of the first prescription, after a 6-month drug-free period b Association between each covariate and the initiation of GLP-1ra versus initiation of LAI as estimated from the propensity score model; odds ratios from multivariable logistic regression model; odds ratios >1.0 indicate more likely to be initiated on GLP-1ra than LAI c Age is defined as the linear plus quadratic term in the propensity score estimation model but the odds ratios for individual age groups are displayed here for easy interpretation d Pseudo-population of LAI initiators weighted to the distribution of covariates of the GLP-1ra initiators using the propensity score to balance covariates (and therefore control for confounding) e Measured in the 12 months before drug initiation (the date of the first prescription)
results. Findings from first treatment carried forward analyses, which do not suffer from potential selection bias and provide a longer follow-up time, also revealed similar estimates to our primary as treated analyses, suggesting that censoring of study participants due to drug changes is not informative with respect to colorectal cancer incidence.
A randomized controlled trial with 3-year follow-up data on the sitagliptin versus placebo revealed similar finding to ours with the 0.3 % colon cancer risk among sitagliptin initiators (21 cases among 7332 initiators) versus 0.5 % risk among placebo (34 cases among 7339 initiators), which, though numerically slightly protective, was not statistically or clinically significant over a similar period of duration of treatment [6] .
The major strength of our study is the utilization of the active comparator, new user, cohort study design, which restricts the study population to initiators of therapies with similar indication [12, 24] . By selecting guideline recommended active comparator drugs, we tried to minimize unmeasured confounding by indication and frailty [12] . While we cannot precisely measure neither the indication nor frailty, we implicitly control for these by selecting an active comparator drug class that is a clinical alternative for the same degree of disease progression as the treatment of interest. This implicit control by study design is very different from the Busual^control for a covariate during the analysis phase because it does not rely on a good measure of the indication or frailty. IQR interquartile range, HR hazard ratios, CI confidence interval, SMR standardized morbidity ratio (weight of 1 given to DPP-4i or GLP-1ra users and PS/(1-PS) to TZD, SU or LAI users, where PS stands for propensity score), NR not reported a Initiation or new use defined as dispensing at least 2 prescriptions within 30 days (90 days for GLP-1ra) after the days' supply of the first prescription, after a 12-month drug-free period (6 months for GLP-1ra). Note that the number of new users presented here represents the cohort to which the lag period of 6 months has been applied b Hazard ratios and 95 % confidence intervals from Cox proportional hazards model for colorectal cancer with baseline treatment as the only independent variable c Age is included as linear and quadratic terms d Hazard ratios and 95 % confidence intervals from propensity-score weighted Cox proportional hazards model (standardized to DPP-4i or GLP-1ra population). Variables used in SMR weighting include demographics (age, age-square, race, sex), comorbidities (such as connective tissue disorder, congestive heart failure, chronic obstructive pulmonary disease, myocardial infarction, depression, gastrointestinal diseases, diabetes mellitus, hypertension, diabetes complications), co-medications (antihypertensives, oral antihyperglycemic drugs, statin, nonsteroidal anti-inflammatory drugs, aspirin, tobacco smoking, alcohol), indicators of health system utilization (number of hospital admissions, emergency department visits, outpatient visits, fecal for occult blood testing, colonoscopy, lipid test, flu shots) e Number of people initiating DPP-4i treatment different in both cohorts because in the DPP-4i versus TZD cohort pair, patients were allowed to be on antihyperglycemic drugs other than DPP-4i and TZD during the washout period. Similarly, in the DPP-4i versus SU cohort pair, patients could be on antihyperglycemic drugs other than DPP-4i and SU during the washout f Not reported due to small cell size according to data use agreement with the Centers for Medicare and Medicaid Services
As a result of our study design, the distribution of most measured risk factors for colorectal cancer was similar between DPP-4i initiators and TZD/SU cohorts even before adjustment using propensity scores. GLP-1ra initiators on the other hand represented a generally healthier and younger group of new users more likely to undergo preventive health services compared to LAI initiators [25] . While LAI is not a perfect active comparator, it has the advantage of being an injectable drug, similar to GLP-1ra. After propensity score weighting, these differences were removed and the HR for the GLP-1ra versus LAI increased substantially. Most of this confounding was due to the health care utilization, which was strongly related to the risk of colorectal cancer diagnosis in our data.
Our study has limitations. Since drug utilization was assessed from pharmacy claims data on dispensed prescriptions, it is possible that patients did not actually initiate the drugs. We attempted to minimize this problem by requiring a second prescription of the same drug class before entering the cohorts. The median duration between the first and second scripts was 30 days for DPP-4i cohorts (44 days for GLP-1ra cohort), and we lost approximately 30 % of each of our cohort pairs due to this requirement. Yet, the proportion of patients excluded was similar between incretins and their comparators, which minimizes the chance of selection bias (Online Resource Appendix Table S13 ).
While our study represents the real world pattern of drug utilization, our major limitation is the short duration of treatment, and thus, our findings should be interpreted cautiously. We observed consistent hazard ratios even 2 years after initiation, but both the number of long-term users and events were small. To minimize the limitation Medicare data, according to primary as treated analyses. Follow-up started from 6 months after the date of the second prescription until the event or any non-colorectal incident cancer (except nonmelanoma skin cancer), discontinuation, switching, or augmentation with the comparator drug with 6 months lag, death, end of enrollment or December 31, 2013. Propensity score weighting is implemented by standardized morbidity ratio weighting in which a weight of 1 is given to DPP-4i or GLP-1ra users and the propensity odds to TZD, SU, or LAI users due to short duration of treatment, we looked at the effect of antihyperglycemic drugs initiation on the colorectal cancer precursors (polyps, adenomas and in situ cases), and results were similar to our primary analyses. We could not distinguish between polyps and adenoma cases due to the absence of separate billing codes in the claims data. The small number of events in our study especially among the GLP-1ra initiators is another limitation of our study. Many GLP-1ra initiators were previously on short and long acting insulin and thus were excluded from our study. This exclusion is, however, necessary to avoid comparing patients not doing well on the established treatment, most likely to be switched to the newest treatment on the market [24] [25] [26] [27] .
A final limitation of our study is that we could not adequately control for smoking, alcohol consumption, and body mass index (BMI), all risk factors for colorectal cancer [28] [29] [30] [31] [32] [33] . We need to point out that while many of these are related to diabetes control and would likely confound any comparison of treated with untreated patients, our active comparator, new user design limits confounding by these variables to the extent that these would influence the choice between two guideline recommended treatment alternatives. In addition, we adjusted chronic obstructive pulmonary disease as a proxy for smoking and major comorbid conditions related to obesity to partially account for confounding by these unmeasured factors [34] .
In summary, we found evidence for no effect of real world patterns of treatment with incretin-based antihyperglycemic drugs (DPP-4i and GLP-1ra) on the short-term risk for colorectal cancer. Although our study is limited by a short median duration of treatment, our findings currently offer the best available evidence based on real world patterns of these treatments and thus should help clinicians make decisions about the relative benefit harm balance of these treatments.
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